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ABSTRACT 
Background: Our study wanted to assess Italian pediatricians’ awareness, experience and beliefs regarding direct-
to-consumer (DTC) genetic tests (GT) in minors, with a focus on those for predisposition to complex disease, lyfestyle, 
athletic ability and other inborn talents. 
Methods: A 28-item questionnaire was administered through the SurveyMonkey® web platform to the 9,086 
members of the Italian Society of Pediatrics for which a valid email address was available. The survey was opened 
from April through November 2017. Statistical analyses were performed using the Graphpad software package. 
Results: 36.2% of the 442 respondents were aware of DTC-GT, but only 23.1% of them felt adequately prepared 
to meet families’ information needs.  The first three sources of knowledge were the Internet (20.98%), magazines/
newspapers (16.78%) and TV/Radio (14.33%), while companies’ direct marketing activity influenced knowledge 
only in 2.45% of the cases.  Only 16.4% of the aware respondents had been already approached for advice. More 
than 95% of the pediatricians who were aware would not advise DTC-GT for lifestyle, athletic performance or other 
inborn skills. 69.2% was unfavourable to susceptibility tests for complex diseases. Most of them expressed an interest 
in learning more and indicated as preferred sources of information public policies issued by professional societies. 
Conclusion: The low awareness and experience and the vendors’ tiny contribution to knowledge suggest a still limited 
penetration of DTC-GT companies in Italy. A great interest in learning more was found. Scientific societies are best 
positioned to support health professionals in this educational goal thanks to their role of trusted sources of information 
and guidance. 
Key words: direct-to-consumer, genetic testing, susceptibility tests, lifestyle/behavioural tests, athletic testing
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INTRODUCTION
Direct-to-consumer (DTC) genetic tests (GT), offered 
on a large scale since 2007 by a growing number 
of commercial companies, involves the marketing and 
selling of the tests directly to the public outside of the 
traditional healthcare system [1]. 
Marketed tests have a broad spectrum of applications. 
Some tests provide information about medically significant 
conditions, such as diagnostic and carrier testing for 
uncommon single-gene disorders (e.g. cystic fibrosis), 
susceptibility testing for common complex conditions 
(e.g. type 2 diabetes) or pharmacogenetic tests for 
drug therapy decisions. However, most of the tests are 
available for minor conditions, personal characteristics 
and non-medical purposes (e.g. eye color, ear wax type, 
bitter taste perception, genetically tailored diet plan, 
propensity to addictions, talent identification, ancestry, 
paternity testing). Furthermore, several companies market 
next-generation sequencing of multigene panels and some 
whole genome or exome scans, providing consumers with 
disease-related and disease-unrelated information at the 
same time [2]. 
DTC-GT has sparked much controversy and can be 
especially problematic when it comes to minors. Children 
and adolescents are a vulnerable population as they lack 
decision-making legal capacity and may be especially 
susceptible to DTC-GT industry marketing influences [3,4]. 
DTC-GT has received a great amount of attention by 
print media and has been advertised or favourably featured 
on some radio and television programs. In addition, given 
the rapid growth of the Internet as a central source of 
health-related knowledge, advertisments and informative 
material provided by the vendors have become prominent 
founts of information regarding DTC-GT [5]. Unfortunately, 
misinformation is far from rare. In 2010 the U.S. Government 
Accountability Office found that 10 out of 15 investigated 
DTC-GT companies “were engaged in some form of 
fraudolent, deceptive, or otherwise questionable marketing 
practices” [6]. In 2012 the European Parliament published 
an internet survey on DTC-GT for health-related purposes, 
that showed that most companies’ websites failed to provide 
reliable scientific foundation for the offered tests, adequate 
protection against misleading interpretation of the need 
for and proper information on their consequences [7]. 
Current research is consistent with these concerns. It has 
been observed that DTC firms frequently make misleading 
claims, overstating tests’ benefits and understating limitations 
and harms [8,9]. In addition, they have been found 
poorly compliant with international guidelines on providing 
information on confidentiality, privacy and secondary use 
of genetic data [10]. 
Existing policy guidelines on minors, mostly addressing 
the DTC provision model in the context of disease-
oriented testing, highlight more potential risks than benefits, 
repeatedly warning away from utilizing such services 
[1,11]. The 2010 statement of the European Society of 
Human Genetics on direct-to-consumer genetic testing 
for health-related purposes declared that its context 
“does not allow for an adequate assessment of the 
competence of a minor” and that it should not be offered 
before the age of legal majority. The rationale behind 
this position is that medical genetic testing, unless of 
health benefits since childhood, should be deferred 
until the person is old enough to fully partecipate in the 
decision-making process [12]. In 2013 the  American 
Academy of Pediatrics (AAP) and the American College 
of Medical Genetics and Genomics (ACMG) released 
a joint statement strongly discouraging the use of DTC-
GT of children “because of the lack of oversight on test 
content, accuracy, and interpretation” [13]. In addition, 
the AAP and the ACMG expressed concerns regarding   
privacy, self-determination and potential alteration of 
family dynamics and recommended the involvement of a 
professional healthcare provider in any type of genetic 
testing on minors [14]. Regrettably, a poor adherence of 
DTC-GT companies to recommendations and professional 
guidelines on predictive and presymptomatic genetic 
testing of children has been observed [15].
In the context of sport, the consensus statement 2015 
of the International Federation of Sports Medicine (FIMS) 
denied scientific grounds for the current use of genetic 
testing in talent identification or training individualization 
to optimize performance. Accordingly, the shared view 
was that no child or young athlete should be exposed 
to DTC-GT to tailor training or select gifted children and 
adolescents [16].  Similar statements have been endorsed 
by the Human Genetics Society of Australasia [17] and 
by the Australian Institute of Sport (AIS) [18]. Furthermore, 
(2017) AIS, FIMS and Athlome Consortium jointly called 
for international collaboration within a shared ethical 
framework for genomic research applied to sport and 
for “resistence against the agendas driven by direct-to 
consumer genetic testing companies” [19]. 
Commercial DNA testing for healthy living, personal 
characteristics and inborn talents outside of sport has been 
given relatively little attention. Among the tests marketed 
directly for use in children and adolescents, information is 
offered “about everything from cognitive abilities to kid’s 
physical attributes”, as put by a DTC firm’s website [20]. 
Actually, tests range from the ability to learn languages to 
music appreciation, aptitude for mathematics, sensitivity 
to second-hand smoke, optimism, faithfulness, shyness, 
emotional control,   even propensity for teenage romance 
and so on. As the popularity of this typology of testing 
has increased, especially   in East Asian countries where 
families are top spenders on private  education, so have 
worries about their consequences. Aside from the lack 
of scientific evidence and some good examples of 
absurdity, critics have argued that marketing messages are 
rhetorical and misleading, conveying a striking picture of 
genetic determinism. As a consequence children may be 
forced into a specific path or career without taking into 
account their wishes and preferences. With this  concern 
in mind, in 2010 the Japan Society of Human Genetics 
warned against DNA testing for minors “related to ability, 
character and future career paths” [21].
Given all the questions surrounding DTC-GT, the central 
gatekeeper role of medical professionals, particularly of 
family physicians, has been highlighted [22]. A number 
of empirical studies support this view, painting a consistent 
picture where consumers of health-related DTC-GT show 
a preference to access tests, interpret results, or making 
healthcare decisions under the guidance of a physician 
[23].This new role represents a significant challenge for 
most physicians not specialized in genetics and the need 
to provide them with the knowledge and skills to properly 
advise patients has been underscored [24]. 
The worlwide proliferation of DTC-GT market and the 
public’s growing  “genetic curiosity” suggest that, despite 
professional warnings, pediatricians too will face an 
increasing pressure for advice from parents considering 
their use in children. 
The aim of this study was to assess Italian pediatricians’ 
awareness, experience, and beliefs about DTC-GT in minors, 
with a focus on tests for predisposition to common complex 
disease, lyfestyle, athletic ability and other inborn talents.
METHODS
A 28-item questionnaire about knowledge, practice 
and attitudes of pediatricians toward the use of DTC-GT in 
minors was proposed to the active members of the Italian 
Pediatric Society, which is open on a voluntary basis to all 
specialists and registrars in pediatrics. 
At the end of April 2017 the 9,086 affiliated 
physicians for which a valid e-mail address was available 
received an invitation to participate in the survey, including 
a short motivational introduction and the questionnaire URL.
The survey was prepared using the web-based 
SurveyMonkey® platform. The invitation and link to join the 
survey were also enclosed in the April-May print issue of 
the Society’s news magazine, which is sent to the postal 
address of all the active Society members. No solicitations 
were sent to non-responders.The survey was closed at the 
beginning of November 2017. 
The survey, approved by the Steering Committee 
of the Italian Pediatric Society, was voluntary and 
confidential. Questionnaires were anonymously recorded.
The questionnaire was subdivided in five domains: 
1. demographic and professional variables (5 
questions) concerning sex, age range (< 30, 
31-40, 41-50, 51-60, >60 years), duration 
of practice (< 5, 5-10, 10-20 and ≥ 20 years), 
professional profile (community based 
pediatrician, hospital pediatrician of the NHS, 
University pediatrician, private pediatrician, 
pediatric registrar, other) and main practice 
location (categorized into Northern, Central, 
Southern and Insular Italy),
2. knowledge and awareness on GT sold directly 
to consumers (3 questions, regarding knowledge, 
information’s sources and perceived adequacy 
to manage family’s and/or adolescent patient’s 
questions and requests); 
3. experiences with patients (7 questions, including 
whether or not they have been asked on DTC-GT 
in 2016 or in past years by families/adolescent 
patients, questions typology, categories of tests 
eventually performed in 2016 by children/
adolescents and age range of tested minors);
4. opinions and attitudes toward DTC-GT (9 questions 
with special focus on tests for multifactorial 
diseases, athletic abilities, other inborn talents 
and lifestyle);
5. educational needs about DTC-GT (4 questions 
concerning interest in learning more, the reasons 
why the respondents did not eventually want to 
learn more, preferred topics and preferences for 
educational delivery methods.
Apart from the five personal and professional queries, 
nine questions were dichotomic (yes/no; none/n°) and 
fourteen were multiple-choice with more than one possible 
answer. Six  multiple-choice questions included the choice 
“other”, with a “please specify” request allowing entry of 
free text.
Statistical analysis was conducted using the Graphpad 
software package (San Diego, CA, USA). The respondents’ 
personal characteristics and questionnaire responses 
were described using frequencies and percentages. Chi-
square test was used to determine statistical significance. 
The significance level was considered as p<0.05.
RESULTS
A total of 442 physicians filled the questionnaire, 
resulting in a response rate of 4,86% of all active members 
of the Society (442/9,086). The proportion of missing 
answers to survey questions over all the items was less than 
1%. No significant differences in survey response rates of 
the 6,000 female and 3,086 male society members were 
found (X2 = 0.017, df = 1, n.s. ).
The demographic and professional variables of the 
respondents are summarized in Table 1.
Most of the participants (282/442, 63.8%) had no 
awareness of DTC-GT, while 160 (36.2%) were aware, 
although only 23.1% (37/160) of them felt adequately 
prepared to meet families’ information needs.
A significantly larger percentage of male respondents 
than female respondents were aware of DTC-GT (X2 = 
13.4, df = 1, p < .001). 
Increasing age was significantly associated with 
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(6/20) and 7-10 years in the remaining 20% (4/20). 
The distribution of performed DTC tests according to their 
main categories (multichoice query with 27 answers) 
shows that the prevailing ones are carrier (9/27; 33.3%) 
and diagnostic testing (9/27; 33.3%), followed by 
presymptomatic and genetic relatedness tests (in both 
cases 3/27; 11.1%). In 2 cases (7.4%) and in 1 (3.7%) 
respectively, susceptibility and nutrigenetic testing had 
been performed.
A very large majority of the pediatricians who were 
aware would not advise DTC genetic testing for predicting 
sports performance and athletic talent  (96.9%, 155/160) 
nor for lifestyle or inborn skills outside of athletics (96.3 %, 
154/160). Only five (3.1%) and six pediatricians (3.7%), 
respectively, support their use. The given reasons are 
summarized in Table 5.
69.2% (110/159, one answer was left blank) of the 
aware respondents had a negative view of DTC genetic 
tests for risk predictions of common complex diseases, 
many of which arise in adult life, while 49 (30.8%) have 
the opposite opinion. The reasons behind their judgements 
are outlined in Table 6. 
76.9% (123/160) reported feeling unprepared 
to answer patient questions regarding DTC-GT and 
more than four-fifth of  the aware physicians (133/160; 
83.1%) reported wanting to learn more about DTC-GT. 
The reasons why 27 respondents did not want to learn 
more were (out of 37 answers to this multichoice query): 
a) DTC genetic testing will not have a significant impact 
on the provision of health care in the next future or before 
my retirement   (43.2%, 16/37); b) learning postponed 
until the issue will come up in the care context of specific 
patients (27%, 10/37); c) I will not face enquiries from 
the families about this topic (10,.8%, 4/37); d) lack of 
higher awareness (X2 = 23.8, df = 4, p < .001) and in the 
two older age ranges no significant differences in female 
versus male awareness were observed (51-60 years X2 = 
1.649, df = 1 ; n.s.; >60 years X2 = 0.029, df = 1, n.s.). 
With regard to geographic area of main practice no 
significant trend north-south was observed. 
Table 2 shows the contribution of the various sources of 
knowledge on DTC-GT, based on 286 answers provided 
for this multiple-choice query by the physicians who were 
aware. The majority of them (88.1%, 141/160) marked 
at least two sources of information. 
The majority of respondents who were aware of 
DTC-GT (83.6%, 133/159, one answer was left blank) 
had never discussed the topic with a patient’s family or an 
adolescent patient nor were asked to see their results. Only 
16.4% (26/159) of them had already been approached 
by families asking questions before eventual testing or 
advice following its result. During 2016 a total of 60 
clinical interactions were reported by 19 pediatricians 
(11.9%) and 11 of them (6.9%) had at least one family/
patient bring in test results (in total 20 cases, range 1-3 
cases for respondent). Categories of questions asked by 
families or adolescent patients are summarized in Table 3, 
while the types of tests for which information or advice was 
sought are reported in Table 4.
20 families brought the results of DTC-GT to the 
consultation. The age range of tested children was up to 
2 years in 50% of the cases (10/20), 2-6 years in 30% 
TABLE 2. Information sources about dtc genetic testing 
Total answers = 286 ^
SOURCE n° and (%)
Internet 60 (20.98%)
Magazines and newspapers 48 (16.78%)
Tv/Radio 41 (14.33%)
Medical Journals 38 (13.29%)
Patients’ Families/Patients 30 (10.49%)
Scientific Meetings 23 (8.04%)
Physicians and other healthcare providers 21 (7.34%)
Professional Societies 14 (4.90%)
Selling Companies 7 (2.45%)
Other * 4 (1.40%)
^ Respondents could choose multiple answers
* Including advertising in pharmacy, personal acquaintance with a seller or with consumers of DTC-GT 
TABLE 3. Categories of questions asked by families/patients about DTC genetic testing
Total answers = 78 *
QUESTION CATEGORY n° and (%)
If you would advise testing 21 (26.92%)
Information about specific tests 13 (16.67%)
Whether clinical test results may change patient’s health care 12 (15.38%)
Information about testing benefits 12 (15.38%)
Whether test results may help  improving lyfestyle and/or obtaining better performances 11 (14.10%)
Information about selling companies 3 (3.85%)
What you would do in my position 3 (3.85%)
Cost/benefit appropriateness  3 (3.85%)
*Respondents could select more than one answer
TABLE 1. Demographic and professional characteristics of the respondents (n=442)
SEX N° %
Female 292 66.07%
Male 147 33.25%
Not declared 3 0.68%
AGE RANGE
< 30 y 10 2.26%
31-40 y 100 22.62%
41-50 y 74 16.74%
51-60 y 127 28.73%
>60 y 130 29.42%
Not declared 1 0.23%
PROFESSIONAL PROFILE
Family pediatrician 156 35.29%
Hospital pediatrician (NHS) 190 42.99%
University pediatrician 23 5.20%
Pediatricians working in private health structures 22 4.98%
Registrar in Pediatrics 16 3.62%
Other 33 7.47%
Not declared 2 0.45%
YEARS OF PRACTICE
<5 y 26 5.88%
5-10 y 68 15.39%
10-20 y 87 19.68%
>20 y 258 58,.37%
Not declared 3 0.68%
REGION OF THE MAIN PROFESSIONAL PRACTICE 
Northern Italy 224 50.68%
Central Italy 112 25.34%
Southern Italy 76 17.19%
Insular Italy 30 6.79%
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time to learn (8.1%, 3/37). In the “other” category two 
pediatricians (5.4%) stated that that primary responsibility 
for counselling would lie with other specialists, mainly 
clinical geneticists; another one felt already competent 
and the last one was predominantly interested in different 
areas of genetics. 
When asked to indicate from a multichoice list 
which areas need particular  strengthening in education 
programmes, the most common of the 573 provided 
answers were: a) evidence-based guidelines to adequately 
manage patients with increased genetic risks after testing 
(19%, 109/573); b) in-depth insight on the available 
types of DTC-GT (18.8%, 108/573); c) reliability of DTC-
GT (17.6%, 101/573); d) how to interpret test results 
(16.1%, 92/573); e) associated ethical issues (14%, 
80/573).  The least chosen options were: a) informative 
resources dedicated to physicians (7.2%; 41/573), 
b) informative resources dedicated to patients (4.5%; 
26/573), c) characteristics of DTC companies and of their 
services (2.8%, 16/573).
Four sources were the most highly endorsed for future 
learning, cumulatively accounting  for almost four fifth of 
the 415 answers to this multi-choice query: public policies 
(e.g. position statements and guidelines) issued by scientific 
societies  (24.6%, 102/415), journal articles (22.6%, 
94/415), professional medical meetings (e.g. seminars, 
congressional sections, residential courses; 16.9%, 
70/415) and meeetings with medical genetics specialists 
(14.5%, 60/415). Multimedia learning platforms and 
trusted internet websites accounted respecitively for 8.4% 
(35/415) and 7 % (29/415) of the preferences. 
Brochures, magazine and newspaper articles, TV/Radio 
programs and face-to-face encounters with representatives 
of DTC companies were the least chosen resources 
(respectively in 2.4%, 2.4%, 0.7 %, 0.5% of the cases).
DISCUSSION
We sought to assess Italian pediatricians’ awareness, 
experience and beliefs regarding DTC-GT in minors, with 
a focus on those for predisposition to complex disease, 
lyfestyle, athletic ability and other inborn talents. 
Most of our respondents (63,8%) were unaware of 
DTC-GT. The awareness of DTC-GT among physicians 
varies considerably by specialization and across years and 
countries. To our knowledge, only one study has has been 
published in Italy to date, disclosing a 31.6% awareness 
among family physicians in 2014 [25]. This value is not 
significantly different from the 36.2% actually found among 
TABLE 5. Respondents’ opinions  concerning DTC-GT for athletic abilities, lyfestyle and inborn talents outside of athletics
DTC GENETIC TESTING FOR 
ATHLETIC ABILITIES
DTC GENETIC TESTING FOR 
LYFESTYLE AND INBORN 
TALENTS OUTSIDE OF ATHLETICS
A- CONCERNS EXPRESSED BY AWARE RESPONDENTS 
WHO WOULD NOT ADVISE DTC-GT 
Total answers = 400
n° and % *
Total answers = 409
n°and % *
Doubts about test validity and utility and results accuracy 93 (23.25%) 101 (24.7%)
In minors genetic testing shouldn’t be done without the 
involvement of their doctors  86 (21.5%) 80 (19.6%)
Potential alteration of family dynamic 83 (20.75%) 87 (21.3%)
Not evidence-based 68 (17%) 64 (15.6%)
Detrimental to minors’ autonomy 63 (15.75%) 66 (16.1%)
Privacy concern 7 (1.75%) 11 (2.7%)
B – REASONS ENDORSED BY AWARE RESPONDENTS 
WHO WOULD ADVISE DTC-GT 
Total answers = 5
n° and %
Total answers = 11
n° and %
Tests are just indicative but they don’t harm 2 (40%) 3 (27.27%)
Tests can select what kind of sports minors are likely to be 
good at /To support family’s educational task 1 (20%) 2 (18.19 %)
Tests can implement minors’ prospect of success (+/- in sport) 1 (20%) 1 (9.09%)
Tests are scientifically valid 1 (20%) 1 (9.09%)
To meet family’s needs and expectations 0 3 (27.27%)
Test have a favourable cost-benefit ratio 0 1 (9.09%)
* Respondents could select more than one answer
TABLE 6. Reasons endorsed by aware respondents who, respectively, would not advise or advise DTC-GT for common complex diseases
“would not advise” Total answers = 251* “would advise” Total answers = 103*
Reason n° and % Reason n° and %
In minors genetic testing shouldn’t be 
done without the involvement of their 
doctors 
63 (25.1%) Promotion of lyfestyle changes 36 (35%)
Difficult interpretation of the results 61 (24.3%) Promotion of screening test 31 (30.1%)
Doubts about test validity and utility 
and results accuracy
54 (21.52%) To get a diagnosis potentially useful 
also for other family members 
28 (27.2%)
No guidelines to reduce risk since 
childhood 44 (17.53%)
Modification of the plan of 
scheduled visits for minors with 
increased risk of disease 
7 (6.8%)
Concern about privacy and minors’ 
autonomy
24 (9.56%) More respectful of privacy 1 (0.9%)
Other^ 5 (1.99%) Other 0
* Respondents could choose more than one answer
^ Other responses, submitted as free text, can be categorized as follows: a) correct lifestyle should be pursued indipendently from genetic test b) 
familial history is useful to detect risks, c) DTC-GT results may be misinterpreted by the family. 
TABLE 4. Categories of tests for which families sought information or advice in 2016
Total answers = 47 *
CATEGORY n° and (%)
Carrier testing 16 (34%)
Diagnostic tests 7 (14.9%)
Pre-symptomatic tests 6 (12.8%)
Genetic relatedness tests 6 (12.8%)
Susceptibility tests to common multifactorial conditions 5 (10.6%)
No specific category, generic questions 4 (8.5%)
Nutrigenetic tests 3 (6.4%)
Pharmacogenetic tests 0
Genetic ancestry testing 0
Sport tests 0
Lifestyle/behavioural tests 0
Phenotype tests 0
* Respondents could select more than one answer
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investigated pediatricians. By contrast, in a 2008 US survey 
pediatricians were among the most aware physicians (50%) 
of personal genomics offered directly to consumers [26]. 
Some empirical studies have looked at the awareness of 
other medical specialists regarding DTC-GT. 68.4% and 
86% of the Japanese and European clinical geneticists, 
surveyed respectively in 2007 and 2010, were aware 
of DTC-GT [27,28]. The level of awareness was 38% 
among general practitioners and 38.7% among  primary 
care physicians investigated several years ago respectively 
in Japan and in North Carolina (US) [27,29]. The 2012 
article by Ram et al. indicates that the proportion of New 
Zealanders general practitioners who had heard about DTC 
genetic testing was 47.8% [30].
According to our respondents the primary information 
source about DTC-GT is the Internet, similarly to the previous 
Italian study, confirming the web’s growing role as a 
medium for knowledge transfer. Non-traditional players in 
medical education  (TV, radio, magazines and newpapers) 
jointly account for more than 30% of information sources. 
By contrast, medical journals, scientific meetings and 
professional societies, taken together, constitute around 
26% of the learning sources. Direct marketing activities of 
the companies influenced the knowledge in 2.45% of the 
cases. This percentage is slightly higher than that observed 
in the 2014 Italian survey (1.3%), but much lower of 
the 13.5% indicated by the primary care providers 
investigated in US by Powell et al.[29] and of the 11.7 
% disclosed by Japanese general practitioners surveyed by 
Ohata et al. [27], suggesting a still low market penetration 
of DTC companies in Italy.  
Given the promotional nature of the informative 
material of for-profit companies and the reductionist 
approach to genome often conveyed by popular media, 
these data highlight the importance that institutional bodies 
monitor and anticipate upcoming health market trends 
so to provide professionals with timely and unbiased 
information, as exempified by the Australian model [31] 
and envisaged by the Italian plan for the innovation of 
Health System based on Omic Sciences [32]. 
Direct experience with DTC-GT is obviously lower 
than awareness. In the year prior to survey (2016) 11.9% 
of the aware respondents had at least one family/patient 
asking questions before or after testing, and 6.9% had at 
least one family/patient bring in test results. Interestingly, 
most testing were done to look for mutations in single 
genes related to monogenic disorders or to detect genetic 
relatedness (e.g. paternity test), while tests related to 
conditions where there are both genetic and enviromental 
influences were very infrequently seen and limited to 
susceptibility testing to common complex diseases and to 
nutrigenomic.  No tests for athletic abilities, lyfestyle and 
inborn talents outside of athletics were declared.
With regard to DTC provision model of genetic testing 
to minors, the large majority of respondents who were 
aware expresses views in agreement with guidelines and 
statements of scientific societies (12,13,14,16,17,18). 
Only less than 4% would advise testing for athletic abilities, 
lifestyle and other inborn talents. The position on DTC 
susceptibility testing  is more nuanced and sligthly more 
than 30% would advise them. 
A considerable 83.1% of the respondents who were 
aware expressed the desire of learning more about DTC-
GT. Providers holding the opposite view mostly endorsed 
the reason of the unlikely impact of DTC-GT on their 
care practice. However, caution should be expressed 
on this point. Proliferation of DTC-GT, marketing efforts 
and growing public awareness could rapidly  increase 
demand for these tests. In addition, empirical research 
shows that  public's attitude toward pediatric testing can 
be unaligned with experts’ views.  McGuire et al. found 
that 52% of social networkers having used or being 
interested in personal genome testing for themselves would 
consider using for their children and that 63% agreed 
that parents should be able to have their children tested 
[33].  Tercyak et al.  reported that parents enrolled in 
an observational study on genetic test for common adult-
onset diseases are inclined to have their children tested 
too [34]. A similar view is held by mothers participating 
in BRCA1/2 testing [35]. Testing of minors for carrier 
status to assess future reproductive risks and for adult-onset 
conditions for which no prevention/treatment is available 
during childhood is supported, respectively, by 60% and 
47% of British adults surveyed by Shkedi-Rafid et al. [36] 
and healthcare professionals regularly face requests from 
parents for these tests [37]. 
However, in agreement with several other studies 
[38], most pediatricians, though aware, felt unprepared  to 
appropriately counsel  on DTC-GT and expressed the desire to 
learn more. The large majority of those desiring to learn more 
trust the scientific societies and the traditional medical education 
channels, that account for almost 80% of the preferred sources 
for future learning. Interestigly, despite the growing number of 
online resources available to assist integrating genomics into 
medical care, multimedia learning platforms and websites 
are perceived less useful than traditional channels, together 
accounting for about 15% of the preferences. The finding is 
somewhat surprising since Italian pediatricians frequently use 
the Internet during their practice [39]. 
We acknowledge that this study has several 
limitations. First, the overall response rate is very low 
as no attempts were made to incentivize responses. 
Second, the respondent group may be more highly 
motivated than providers nationally. Although this is not 
a representative sample, the results offer a window into 
the awareness, experiences and beliefs of pediatric 
professionals regarding DTC-GT, still largely lacking. We 
hope that in the future more systematic studies of DTC-GT 
will  ascertain diffusion, counselling behaviour and ethical 
aspects associated with this new phenomenon.
CONCLUSION
Though our survey show low awareness and limited 
experiences of Italian pediatricians with DTC-GT, the 
continuing expansion of this market and the strong 
parent-pediatrician alliance let us predict that pediatric 
professionals will increasingly be engaged in discussion 
involving this complex matter. In addition, a direct-
to-physician advertising of commercial genetic tests, 
especially in the pharmacogenomics field, is foreseeable 
in the next future [40].
Our data indicate also that pediatricians are interested 
in learning more about DTC-GT. Scientific societies are 
best positioned to support health professionals in this 
communication challenge thanks to their role of trusted 
sources of information and guidance within the physician 
community. They can develop statements and guidelines 
shaping care practice, disseminate information through 
specialistic journals and organise continuing medical 
education  courses, taking into account pediatricians’ 
preferences for areas such as interpretation of results and 
management of patients with increased genetic risks after 
testing, clinical validity and clinical utility of the tests and 
ethical issues associated with DTC-GT. In our opinion, a 
special effort should be dedicated to facilitate physicians’ 
access to online information sources that must be user-
friendly, reliable, unbiased and regularly updated
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